PureTech Health plc (PRTC)

PureTech Health plc is a biotherapeutics company founded by Daphne Zohar, who has led it as chief executive, with its operating base in Boston, Massachusetts and its parent company incorporated in the United Kingdom. The group uses a hub-and-spoke model in which it discovers and develops therapeutic candidates, often through subsidiaries and founded entities, and then seeks outside capital or partners for individual programs.

Its programs spanned areas such as immunology and inflammation, fibrosis, neuroscience and lymphatic biology. Over time it generated dozens of therapeutic candidates, and three of its products or product-bearing companies obtained approval from the U.S. FDA. Among its most notable programs was KarXT, developed by Karuna Therapeutics, in which PureTech held an interest. Karuna was acquired by Bristol Myers Squibb in 2024, and the drug was approved by the FDA later that year for schizophrenia.

PureTech's ordinary shares have been listed on the London Stock Exchange since 2015, and the company later added a U.S. listing in the form of American Depositary Shares on Nasdaq in 2020, each ADS representing ten ordinary shares. The U.S. listing gave the company access to American biotech investors, while its governance framework and much of its shareholder base remained in the United Kingdom.

On April 29, 2026, PureTech announced that it had notified Nasdaq of its intention to voluntarily delist its ADSs. The board said that a dual listing was no longer necessary, because most trading volume, liquidity and price discovery occurred on the London Stock Exchange and most investors were UK-based. It also cited the cost and regulatory burden of maintaining two listings.

PureTech filed a Form 25 with the SEC on or about May 11, 2026, with the delisting expected to take effect about ten days later and the last trading day on Nasdaq on or about May 20, 2026. The company said that following delisting, the ADSs were expected to trade over the counter through a sponsored Level 1 ADR program, and that ADS holders did not need to take any action.

PureTech also stated its intention to file a Form 15F to deregister its securities under U.S. law and end its SEC reporting obligations, with deregistration effective no later than 90 days after filing absent SEC objection. Its ordinary shares continue to trade on the London Stock Exchange, which became its primary trading venue.